Veracyte Market Risk Adjusted Performance
| VCYT Stock | | | USD 33.28 -0.20 -0.60% |
The Market Risk Adjusted Performance profile for Veracyte is based on historical price and volume observations. All inputs reflect available trading data across supported markets. Normalization methods and data feeds may affect reported values. Related screening structures are referenced through
Equity Screeners. Veracyte has a market cap of 2.6 B, operating margin of 17.5%, ROE of 5.34%. For allocation context, review
World Market Map. Allocation details are provided as informational context. Allocation context is based on the most recent position data. No forward-looking guarantees are expressed or implied by this data. This includes a position in Veracyte. The allocation reflects this within the position set. Each holding is sized according to the methodology applied to the portfolio. All values are based on available data and provided as reference information. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in private.
For information on how to trade Veracyte Stock refer to our
How to Trade Veracyte Stock guide.
Veracyte has current Market Risk Adjusted Performance of 1.06.
MRAP | = | ER[a] + (1/BETA - 1) | X | ER[a] - RFR) |
| = | 1.06 | |
| ER[a] | = | Expected return on investing in Veracyte |
| RFR | = | Risk Free Rate of return. Typically T-Bill Rate |
| BETA | = | Beta of the asset with market or selected benchmark. |
Market Risk Adjusted Performance Peers Comparison
Market Risk Adjusted Performance Relative To Other Indicators
Veracyte maintains a
third standing in market risk adjusted performance relative to competitors. It is currently under evaluation in maximum drawdown relative to competitors yielding
13.26 of Maximum Drawdown per Market Risk Adjusted Performance. For Veracyte, Maximum Drawdown stands at
13.26 times Market Risk Adjusted Performance
Other Technical Indicators